Study identifier:2993-119
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
An Open Label Study to Examine the Long Term Effect on Glucose Control (HbA1c) and Safety and Tolerability of Exenatide Given Two Times a Day to Subjects with Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Phase 3
No
exenatide
All
456
Interventional
18 Years - 70 Years
Allocation: N/A
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
N/A
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Exenatide Exenatide 5 mcg for 4 weeks (transition) then 10 mcg to study termination | Drug: exenatide subcutaneous injection, 5 mcg, twice a day for 4 weeks (transition period), then 10 mcg twice a day till study termination Other Name: Byetta Other Name: exendin-4 Other Name: AC2993 |